Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
Takeda Pharmaceutical said on June 6 that a two-dose vial version of its COVID-19 vaccine Nuvaxovid, licensed by Novavax, will be supplied as a shot adapted to the JN.1 strain of the novel coronavirus in Japan. Takeda filed the two-dose…
To read the full story
Related Article
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
September 2, 2024
- BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
August 20, 2024
- Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- Japan Ends Supply of Takeda/Novavax’s COVID Jab, 7.14 Million Doses Discarded
December 26, 2023
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…